0.6127
price down icon4.41%   -0.0283
 
loading

Finanzdaten der Lyell Immunopharma Inc-Aktie (LYEL)

Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
Enddatum des Zeitraums 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31
Periodenlänge 3 Monate 3 Monate 3 Monate 3 Monate 3 Monate
Revenues
76.92%
0.003
0.013 0.025 0.027 0.065
Operating Expenses
6.62%
55.58
59.52 59.06 65.93 62.62
Benefits Costs and Expenses
-
- - - -
Costs And Expenses
6.62%
55.58
59.52 59.06 65.93 62.62
Operating Income/Loss
6.61%
-55.58
-59.51 -59.04 -65.91 -62.56
Nonoperating Income/Loss
177.41%
-5.092
6.578 8.186 2.015 -4.403
Income/Loss From Continuing Operations Before Tax
76.92%
0.003
0.013 0.025 0.027 0.065
Income/Loss From Continuing Operations After Tax
14.62%
-60.67
-52.93 -50.85 -63.89 -66.96
Net Income/Loss
14.62%
-60.67
-52.93 -50.85 -63.89 -66.96
Preferred Stock Dividends And Other Adjustments
-
- - - -
Attributable To Noncontrolling Interest
-
- - - -
Basic Average Shares
41,856%
254.25
0.606 251.32 250.20 249.59
Diluted Average Shares
41,856%
254.25
0.606 251.32 250.20 249.59
Basic Earnings Per Share
20.00%
-0.24
-0.20 -0.20 -0.26 -0.27
Diluted Earnings Per Share
20.00%
-0.24
-0.20 -0.20 -0.26 -0.27
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic
-
- - - -
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
Kapitalisierung:     |  Volumen (24h):